The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Long-term survival outcome of multi-institutional prospective phase II trial of conversion surgery: CCOG1403.
 
Seiji Ito
Honoraria - Otsuka; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst)
 
Yuichi Ito
No Relationships to Disclose
 
Daisuke Kobayashi
No Relationships to Disclose
 
Hidenobu Matsushita
No Relationships to Disclose
 
Yuri Tanaka
No Relationships to Disclose
 
Yasuhiro Kodera
Honoraria - Abbvie; Amgen; Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; Lilly Japan; Miyarisan Pharmaceutical; MSD K.K; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Tsumura & Co.; Yakult Honsha
Consulting or Advisory Role - Daii Sankyo
Research Funding - abbott Japan (Inst); Bayer (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Kaken Pharmaceutical (Inst); Lilly Japan (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Otsuka (Inst); Otsuka (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); TOA Pharmaceuticals (Inst); Tsumura & Co. (Inst)